Arch Biopartners (ARCH) AI Stock Analysis

• Market Cap: C$122.59M
• Dividend Yield: N/A
• Average Volume (3M): 14.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: N/A
• EPS Growth: -78.59%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 65,906,364
• 10 Day Avg. Volume: 13,705
• 30 Day Avg. Volume: 14,757
• PEG Ratio: -3.08
• Price to Book (P/B): -25.30
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -40.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 26 Underperform
• Price Target: ―

Arch Biopartners is currently facing significant financial distress with no revenue generation, large operational losses, and negative equity. These factors heavily weigh down its overall score. Technical indicators are mixed, showing some bearish signals but not overly negative. Valuation is also a concern, with a negative P/E ratio and no dividend yield. Strategic improvements are crucial for future stability and growth.

Arch Biopartners Business Overview & Revenue Model

Company Description

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.

How the Company Makes Money

Arch Biopartners primarily generates revenue through the development and commercialization of its drug candidates. The company invests in the research and development of its proprietary technologies, aiming to bring them to market either independently or through strategic partnerships with larger pharmaceutical companies. Revenue streams include potential licensing agreements, milestone payments, and royalties from successful commercialization of its drug candidates. Additionally, Arch Biopartners may receive government grants or research funding to support its development efforts, particularly for projects addressing unmet medical needs.

Arch Biopartners Financial Statement Overview

Summary

Arch Biopartners exhibits severe financial challenges across all primary financial statements. The absence of revenue, large operational losses, negative equity, and reliance on financing indicate a precarious financial position. Strategic interventions are needed to stabilize and improve financial health.

Income Statement

Arch Biopartners is facing significant challenges in its income statement. The company has reported zero revenue in the latest year, indicating a complete halt in sales or service income. Historical data shows a declining trend in revenue with consistent losses, as evidenced by negative EBIT and net income margins. The lack of profitability and revenue growth are major concerns.

Balance Sheet

The balance sheet reflects a highly leveraged position with negative stockholders' equity, signaling financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which poses a significant risk. Total liabilities surpass total assets, indicating insolvency. There is a negative equity ratio, highlighting financial distress.

Cash Flow

Arch Biopartners has negative free cash flow, reflecting insufficient cash generation from operations to cover capital expenditures and operating needs. With no operating cash flow and continuous negative free cash flow, the company is reliant on external financing, as seen in positive financing cash flows.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
0.00	0.00	1.98M	964.68K	3.89M	67.89K
	Gross Profit
-473.10K	0.00	-128.99K	-502.88K	-149.79K	-2.12M
	EBIT
-4.46M	-3.95M	-3.36M	-1.39M	-1.16M	-4.63M
	EBITDA
-1.44M	-3.53M	-335.87K	-101.42K	-77.02K	-4.45M
	Net Income Common Stockholders
-2.45M	-3.92M	-3.33M	-1.08M	-1.17M	-4.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
54.85K	2.97K	831.27K	506.35K	448.24K	653.68K
	Total Assets
533.53K	935.62K	1.17M	621.64K	2.67M	741.30K
	Total Debt
2.83M	2.77M	5.02M	4.41M	5.16M	3.39M
	Net Debt
2.77M	2.77M	4.18M	3.91M	4.72M	2.74M
	Total Liabilities
4.79M	5.28M	6.68M	5.09M	6.55M	4.61M
	Stockholders Equity
-4.26M	-4.35M	-5.51M	-4.47M	-3.88M	-3.87M
Cash Flow		Free Cash Flow
-2.23M	-2.33M	-234.08K	-1.08M	-2.98M	-1.90M
	Operating Cash Flow
-2.23M	-2.33M	-234.07K	-1.08M	-2.98M	-1.90M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
2.01M	1.50M	559.00K	-421.37K	2.78M	2.16M

Arch Biopartners Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Positive. The current price of 1.86 is above the 20-day moving average (MA) of 1.76, above the 50-day MA of 1.75, and above the 200-day MA of 1.81, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 64.16 is Neutral, neither overbought nor oversold. The STOCH value of 89.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ARCH.

Arch Biopartners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
ARCH	26 Underperform	C$122.59M	―	90.17%	―	―	-78.59%
ONCY		$31.78M	―	-211.24%	―	―	―
MSCLF		$73.38M	―	-64.18%	―	―	―
MDNA	53 Neutral	C$71.18M	―	-149.09%	―	―	-67.03%
FENC		$237.76M	―		―	―	―
EPRX	45 Neutral	C$193.35M	―	-108.05%	―	―	―